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Heart Failure
Blocking of Frizzled Signaling With a Homologous Peptide
Fragment of Wnt3a/Wnt5a Reduces Infarct Expansion and
Prevents the Development of Heart Failure After
Myocardial Infarction
Hilde Laeremans, PhD; Tilman M. Hackeng, PhD; Marc A.M.J. van Zandvoort, PhD;
Victor L.J.L. Thijssen, PhD; Ben J.A. Janssen, PhD; Harry C.J. Ottenheijm, PhD;
Jos F.M. Smits, PhD; W. Matthijs Blankesteijn, PhD
Background—The molecular pathways that control the wound healing after myocardial infarction (MI) are not completely
elucidated. One of these pathways is the Wnt/Frizzled pathway. In this study, we evaluated Frizzled as a novel
therapeutic target for MI. These Frizzled proteins act as receptors for Wnt proteins and were previously shown to be
expressed in the healing infarct.
Methods and Results—Wnt/Frizzled signaling has been studied for decades, but synthetic ligands that interfere with the
interaction between Wnts and Frizzled have not been described to date. Here we report the selection of 3 peptides
derived from regions of high homology between Wnt3a and Wnt5a that act as antagonists for Frizzled proteins. UM206,
the peptide with the highest affinity, antagonized the effect of Wnt3a and Wnt5a in different in vitro assays.
Administration of UM206 to mice for 5 weeks, starting immediately after the induction of MI, reduced infarct expansion
and increased the numbers of capillaries and myofibroblasts in the infarct area. Moreover, heart failure development was
inhibited by this therapy.
Conclusions—Blocking of Frizzled signaling reduces infarct expansion and preserves cardiac function after MI. Our findings
underscore the potential of Frizzled receptors as a target for pharmacotherapy of cardiac remodeling after MI. (Circulation.
2011;124:1626-1635.)
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The importance of Wnt signaling in developmental pro-cesses like cell proliferation, differentiation, and migra-
tion has been recognized for decades.1,2 Wnt signaling has
also been implicated in several diseases including cancer.3,4
Although less well studied, there is growing evidence for a
role of Wnt signaling in cardiovascular diseases, particularly
in the remodeling that takes place in response to myocardial
infarction (MI).5–8 The underlying mechanism of Wnt signal-
ing in cardiovascular diseases, however, is fundamentally
different from that in, for example, colon cancer, in which
mutations in the downstream signaling pathway lead to
uncontrolled signaling and contribute to cell proliferation in
the primary tumor. In cardiovascular diseases, no such
mutations have been found to date. Instead, the increased
expression of components of the Wnt signaling pathway
suggests an activation rather than a disorder of the pathway.7,8
Clinical Perspective on p 1635
The involvement of Wnt signaling in multiple disease
processes has fueled an intensive search for compounds that
can modulate the activity of this pathway.7,9–11 The major
focus of this research has been on the signal transduction
pathway where -catenin acts as a second messenger. The
degradation of -catenin is controlled by a complex contain-
ing casein kinase I, glycogen synthase kinase 3, axin, and
adenomatous polyposis coli gene product.4 Several well-
known compounds can attenuate Wnt signaling, including
LiCl, vitamins A and D, and nonsteroidal anti-inflammatory
drugs.10 Moreover, novel drugs that inhibit glycogen synthase
Received July 9, 2010; accepted July 5, 2011.
From the Departments of Pharmacology (H.L., B.J.A.J., H.C.J.O., J.F.M.S., W.M.B.), Biochemistry (T.M.H.), and Biomedical Engineering
(M.A.M.J.v.Z.), Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands; and Angiogenesis Laboratory, Department
of Radiotherapy and Medical Oncology, VU Medical Center, Amsterdam, Netherlands (V.L.J.L.T.).
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.110.
976969/-/DC1.
Correspondence to W. Matthijs Blankesteijn, PhD, Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht,
Maastricht University, 50 Universiteitssingel, 6229ER Maastricht/PO Box 616, 6200MD Maastricht, Netherlands. E-mail wm.blankesteijn@
maastrichtuniversity.nl
© 2011 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.110.976969
1626  by guest on March 28, 2012http://circ.ahajournals.org/Downloaded from 
kinase 3 or intervene in the interaction of -catenin and
T-cell factor/lymphoid enhancer factor have been described.12
These compounds hold great promise for the treatment of
cancer, in which -catenin accumulation due to a defective
degradation complex is a hallmark. However, in diseases
characterized by an activated rather than a disordered Wnt
signaling, like cardiovascular diseases, a direct intervention at
the level of the Wnt receptor Frizzled (Fzd) appears to be
preferable.
To activate signaling, Wnt proteins bind to a receptor
complex formed by a member of the Fzd family and a
low-density lipoprotein receptor–like protein.13 This can
evoke different intracellular responses, involving either
-catenin,4 Ca2, or Rho kinase as a second messenger.14
Apart from the interactions between Wnt3a/5a and Fzd-1 and
-2, knowledge about the specific interplay between members
of the Wnt (19 members) and Fzd (10 isoforms) families is
limited,13,15 and research on this topic has been hampered
significantly by the lack of specific ligands.
The aim of the present study was to identify compounds
that prevent the interaction between Wnts and Frizzled and to
characterize their pharmacological and therapeutic properties.
We focused on Fzd-1 and -2 because we have shown
previously that these 2 Frizzled family members are upregu-
lated in the infarcted heart. To this end, we selected regions
of high homology between Wnt3a and Wnt5a that contain at
least 2 cysteines. The presence of cysteines was considered to
be advantageous to obtain a high binding affinity between
peptide and receptor. Regions necessary for excretion or
posttranslational modification of Wnt5a were excluded. This
approach yielded 3 peptides, ranging from 13 to 22 amino
acids in length. We tested their pharmacological properties in
HEK293-TOPflash cells and immortalized cardiac fibroblasts
and selected the peptide with highest affinity, UM206. We
subsequently determined the pharmacokinetic properties of
UM206 and studied the effect of UM206 administration on
the wound-healing process after MI. Finally, we confirmed
that the peptide fragment utilizes the Wnt3a binding site on
Fzd-1 and -2.
Methods
Materials
The HEK superTOPflash cell line was kindly provided by J.
Nathans, and CHO and COS-7 cells were obtained from DSMZ,
Braunschweig, Germany. Cardiac fibroblasts immortalized with
telomerase (CFIT) were developed and characterized in our labora-
tory.16,17 The TOPflash construct was obtained from Upstate (Mil-
lipore, Billerica, MA). The peptides were synthesized in our labora-
tory, but large-scale synthesis of UM206 was performed by
ChemPep, Miami, FL. Active caspase-3 antibody was obtained from
Cell Signaling, Danvers, MA.
Cell Culture and Transient Transfection
CFIT were developed from primary rat cardiac fibroblasts by
inducing stable overexpression of telomerase, as described previ-
ously.17 All cells were cultured in 75-cm2 culture flasks (Corning,
Schiphol, Netherlands) in Dulbecco’s modified essential medium
with L-glutamine (2 mmol/L), 10% fetal calf serum (Invitrogen,
Merelbeke, Belgium), and 1% gentamycin (Sigma-Aldrich, Zwijn-
drecht, Netherlands). Before the experiment was started, the cell
lines were treated with plasmocin 25 g/mL (Invivogen, Toulose,
France) and tested with a MycoAlert mycoplasma detection kit
(Lonza, Rockland, ME). Plasmid DNA was transiently transfected
into the cells with the use of Fugene6 transfection reagent (Roche,
Indianapolis, IN) DNA, according to the manufacturer’s instructions.
Fzd-1, -2, and -4 and Wnt3a and Wnt5a constructs cloned in
pcDNA3.1/hygro (Invitrogen) and -catenin and Fzd-5 constructs
cloned in pcDNA3.0 (Invitrogen) were used. At 24 hours after
transfection, conditioned culture medium, collected from either
control L cells or L cells with Wnt3a or Wnt5a (Invitrogen) was
added, either alone or in combination with antagonist.
Peptide Fragment Synthesis
All peptide fragments were synthesized by manual solid-phase
peptide synthesis with the use of the in situ neutralization/activation
procedure for Boc/Bzl peptide synthesis as described previously.18
Please refer to the extended methods in the online-only Data
Supplement for details.
Luciferase Experiments
For the luciferase experiments in cells that do not overexpress the
TOPflash construct constitutively (ie, CHO and COS-7), transfection
with a TOPflash construct (8 T-cell factor/lymphoid enhancer factor
binding sites cloned into the pTA-Luc vector) was executed. Lu-
ciferase activity was measured with the use of a luciferase assay
system (Promega, Madison, WI) according to the manufacturer’s
instructions.
Migration Assay
Cells were plated on day 0 and cultured until 70% confluence before
transfection or treatment. Migration assays started 48 hours after
transfection and/or treatment. The time point at which the scratch
was made is indicated as 0 hours. Scratch width was measured at this
time point and also after 6, 12, and 24 hours.17
Quantitative Polymerase Chain Reaction
RNA was isolated with the use of the Trizol method (Invitrogen). For
the reverse transcription polymerase chain reaction, the RNA was
transcribed to cDNA with iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA). Syber green (Eurogentec, Seraing, Belgium) was
used for the detection of cDNA levels, and cyclophilin served as the
housekeeping gene. In Table I in the online-only Data Supplement,
the primer sequences are shown.
Western Blots
Western blotting was performed as described previously.17 The
following primary antibodies were used: -catenin, -smooth mus-
cle actin (both 1:2000, BD Biosciences, Franklin Lakes, NJ), and
-actin (1:2000 Sigma-Aldrich). Anti-mouse immunoglobulin G
1/5000 (Vector Labs Inc) was used as the secondary antibody.
Images of the blots were analyzed with image analysis software
(Qwin Leica, Cambridge, United Kingdom).
Animal Surgery, Echocardiography, and
Hemodynamic Analysis
Male Swiss mice were used (10–12 weeks of age; Charles River,
Maastricht, Netherlands). This strain was previously found to show
strong dilatation of the infarct area, frequently leading to heart
failure. For the pharmacokinetic study, a venous cannula was
implanted through which a bolus injection of UM206 was given, and
blood samples were collected. For the treatment study, the animals
were randomly included into the 3 different experimental groups. In
the treatment study, either UM206 (6 g/kg per day) or saline was
administrated by an osmotic minipump (Alzet 2002 or 2006 for 2 and
5 weeks of treatment, respectively; Alzet, Cupertino, CA). We also
tested an inactive analog of UM206 (CNKASEAMACEL) in the
same dosage. MI was induced under isoflurane anesthesia, and
echocardiography and hemodynamic analyses were performed as
described previously19; please refer to the extended methods in the
online-only Data Supplement for details. All experiments were
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conducted according to international guidelines and approved by the
Committee for Animal Research of Maastricht University.
High-Performance Liquid Chromatography
To determine the plasma concentration of UM206, reached by
subcutaneous infusion with the minipumps, blood samples were
collected from the animals after 14 to 35 days of treatment. Blood
was centrifuged, and the plasma was treated with 1% trifluoroacetic
acid. Analytical high-performance liquid chromatography was per-
formed as described in the extended methods in the online-only Data
Supplement.
Mass Spectrometry
Product-containing fractions were analyzed by electrospray ioniza-
tion mass spectrometry, pooled, and lyophilized. Electrospray ion-
ization mass spectrometry was performed on an Applied Biosystems
SCIEX API 150 EX electrospray ionization quadrupole mass spec-
trometer. Peptide masses were calculated from the experimental
mass to charge (m/z) ratios from all the protonation states observed
in the electrospray ionization mass spectrometry spectrum of a
peptide with the use of Analyst 1.4.2 software (Sciex, Warrington,
UK).
Immunohistochemical Staining
One half of the hearts of the mice were embedded in paraffin and cut
in 4-m sections. The paraffin sections were rehydrated and washed
in phosphate-buffered saline. Azan staining allowed an accurate
determination of the infarct size. To visualize the myofibroblasts in
the infarct area, the sections were incubated with an antibody
directed against -smooth muscle actin (Sigma-Aldrich), followed
by incubation with the peroxidase-conjugated secondary antibody
(Vector Laboratories). Nuclei were visualized by hematoxylin.
Photos were taken with a Leica (CTR500, 63x/0.85) camera and
analyzed with the Quantimet program (QWin/QGo, Leica, Cam-
bridge, UK). An examiner blinded to the groups of the animals
obtained all measurements. Blood vessels were stained with Griffo-
nia simplicifolia I-B4 isolectin and quantified by counting the total
amount of vessels in the infarct area. For the experiments with
rhodamine-labeled UM206, frozen sections (4 m) of mouse kidney
and small intestine were used.
Statistical Analysis
All values are shown as meanSEM. Statistical analyses were
performed with the use of GraphPad Prism software. Differences
between groups were examined for statistical significance with either
1- or 2-way ANOVA as appropriate with the Bonferroni posttest or
unpaired Student t test. Survival curves were calculated with the use
of the Kaplan-Meier method. Statistical analysis of the survival
curves was performed with the log-rank test. A P value 0.05 was
considered a statistically significant difference.
Results
Identification and Pharmacological
Characterization of the Peptidergic
Fzd Antagonists
In Figure 1A through 1C, the 3 regions of high homology
between Wnt3a and Wnt5a that were selected are shown. We
named the peptides UM206 through UM208. To determine
the inhibitory constants of the peptides, HEK293-
superTOPflash cells were transfected with either rFzd-1 or -2
and incubated with recombinant Wnt3a (1 nmol/L) in the
presence of increasing concentrations of either of the peptides
(Figure 1D through 1I). For UM206, a biphasic inhibition
curve was observed that was best fitted with a 2–binding site
model. In the cells transfected with rFzd-1 (Figure 1D), the
Figure 1. Characteristics of the Wnt5a-derived Frizzled (Fzd)-1 and -2 antagonists UM206, UM207, and UM208. A through C, Amino
acid sequences of the 3 peptides, derived from Wnt5a, and their homology with Wnt3a. Identical amino acid residues are indicated by
; conserved substitutions are indicated by . D through I, The inhibitory effects of UM206, UM207, and UM208 tested in an HEK
superTOPflash cell line. The cells were transfected with either Fzd-1 or -2 as indicated and stimulated with Wnt3a (1 nmol/L) as indi-
cated. All results are the average of 3 independent triplicate measurements and are represented as meanSEM. See also Figure I and
Table I in the online-only Data Supplement.
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high affinity site with an IC50 of 2.100.18 109 mol/L was
most prominent, whereas in rFzd-2 transfected cells (Figure
1G), the binding site with an IC50 of 1.690.04 1011 mol/L
was the major binding site. This suggests that UM206 binds
to rFzd-2 with 100-fold higher affinity than to rFzd-1. In
contrast, the inhibition curves for UM207 and UM208 were
best fitted with a single–binding site model; the IC50 values
for Fzd-1 were 4.000.07 108 mol/L (Figure 1E) and
2.060.09 106 mol/L (Figure 1F) and for Fzd-2 1.520.08
108 mol/L (Figure 1H) and 2.110.11 106 mol/L (Figure
1I) for UM207 and UM208, respectively. Administration of
the peptides in the absence of Wnt3a had no effect on the
luciferase activity. These results show that UM206 was the
peptide with the highest affinity for rFzd-1 and -2, and therefore
in the remainder of the experiments this antagonist was used.
Complete inhibition of the Wnt3a-induced luciferase ac-
tivity with UM206-8 was also observed in CHO and COS-7
cells (Figure I in the online-only Data Supplement), although
the fold induction of luciferase activity was considerably
lower in these cells compared with HEK293-superTOPflash
cells. Peptides derived from other regions of Wnt proteins
showed no activity in concentrations up to 10 mol/L (Table
II in the online-only Data Supplement).
UM206 Blocks Fzd-1 and -2 But Not Fzd-4 and -5
In Figure 2A, the specificity of UM206 for Fzd-1 and -2 is
shown. Addition of UM206 in a concentration of 100 nmol/L
abolished the induction of luciferase activity almost com-
pletely in cells overexpressing rFzd-1 and -2 but had no effect
on cells overexpressing hFzd-4 or -5. This was not due to
species differences because UM206 was fully effective in
antagonizing the activation of mouse and human Fzd-1 and -2
by Wnt3a as well (data not shown).
Structure-Activity Relationship of UM206
In Figure 2B, the effect of substitution of each of the
individual amino acids of UM206 by Ala on the inhibition of
Wnt3a-induced luciferase activity is shown. This Ala scan
showed that replacement of Thr,4 Gly,7 and Asp9 affected the
inhibitory properties of UM206 most strongly. The combined
replacement of these 3 amino acids by Ala residues abolished
the antagonizing properties almost completely. Substitution
of either of the Cys residues at position 1 or 11 did not affect
the antagonistic effect of UM206, but simultaneous substitu-
tion of both Cys residues by either Ala or Ser rendered
UM206 completely ineffective. Alkylation of both Cys resi-
dues had the same effect. Substitution of the C-terminal Glu
and Leu by an Ala-Ala sequence reduced the inhibitory
properties of UM206 only slightly, whereas deletion of the
C-terminal Glu and Leu sequence led to a significant reduc-
tion of the potency of UM206. On the basis of these results,
we propose that the antagonistic effect of UM206 is due to the
presence of Thr, Gly, and Asp combined with at least 1 Cys
residue. The peptide derived from the region of Wnt3a homol-
ogous to UM206 (Figure 1A) could also block the Wnt3a-
induced effect but at a slightly lower efficacy than UM206.
UM206 Antagonized the Effects of Wnt3a and
Wnt5a on Immortalized Cardiac Fibroblasts
The overexpression of Fzd-1 and -2 in migrating (myo)fibro-
blasts during infarct healing was one of the first reports of
Figure 2. Selectivity and structure-activity relationships for UM206. A, Selectivity of UM206 for 4 different Frizzled (Fzd) receptors. These
results indicate that UM206 at a concentration of 100 nmol/L specifically blocks Fzd-1 and -2. B, Essential amino acids for antagonistic activ-
ity of UM206 were determined by an Ala scan. Furthermore, some additional modifications of the Cys residues were tested. These results
highlighted 4 important amino acids, namely, Cys, Thr, Asp, and Gly. Replacement of both Cys residues by Ala or Ser residues or alkylation
of both Cys residues abolished the antagonistic properties of UM206. Simultaneous replacement of Thr, Asp, and Gly residues by Ala
strongly reduced the antagonistic properties of UM206. The peptide CNVSSHGIDGCDL, derived from the area of Wnt3a homologous to
UM206 (Figure 1A), also showed antagonistic properties, although the potency was lower than that of UM206. All results are the average of 3
independent measurements and are represented as meanSEM (***P0.001). Statistical test: Student t test.
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activation of Wnt/Fzd signaling in cardiovascular remodel-
ing.20 To assess the functional relevance of Wnt/Fzd signaling
on cardiac fibroblast proliferation, migration, and differenti-
ation, CFIT were used, as described previously.16,17 Admin-
istration of either Wnt3a or Wnt5a attenuated the migration of
CFIT overexpressing either rFzd-1 or -2 (Figure 3A and 3B,
respectively). These effects were blocked almost completely
by addition of UM206 (100 nmol/L) to the culture medium.
Next we investigated the effect on CFIT differentiation and
found that UM206 could completely block the effects of both
Wnt3a and Wnt5a (Figure 3C and 3D).
UM206 Reduced Ventricular Remodeling and
Prevented Heart Failure Development After MI
in Mice
To determine the pharmacokinetic properties of UM206, we
injected 15 g into the tail vein of mice and monitored
the concentration in the blood at different time points. The
half-life was 842 minutes (n24; Figure II in the online-only
Data Supplement). This half-life, combined with the high affin-
ity of UM206, allowed us to test its effects on infarct healing in
mice. To this end, we administered UM206 subcutaneously by
an osmotic minipump (6 g/kg per day); the control group was
equipped with a saline-filled minipump. The minipumps were
implanted at the time of infarct induction and lasted for up to
5 weeks. UM206 administration offered a dramatic improve-
ment of survival: At 5 weeks after MI, 35% of the saline-
treated mice had died, whereas all mice were still alive in the
UM206-treated group (Figure 4A). Postmortem analysis
revealed that the saline-treated animals died from heart
failure, as diagnosed by a wet, foamy aspect of the lungs and
severely elevated wet lung weight. In the surviving saline-
treated mice, wet lung weight was 40% higher than in the
UM206-treated mice at 5 weeks after MI, suggesting devel-
opment of heart failure in the surviving saline-treated mice as
well (Figure 4B). Echocardiography showed an improved
ejection fraction and a 40% reduction in end-diastolic volume
of the left ventricle in the UM206-treated compared with the
saline-treated group, all indicative of a better preservation of
cardiac function (Figure 4C1 and 4C2). Cardiac function was
further assessed with the use of a Millar pressure recording
catheter inserted into the left ventricle. The tangents on the
pressure time curve were significantly steeper in the UM206-
treated groups, resulting in a higher positive dP/dt and a lower
negative dP/dt value (Figure 4D1 and 4D2), underscoring the
positive effect of this treatment on cardiac function after MI.
Similar beneficial effects were observed when UM206 treat-
ment was started at 2 weeks after MI and continued until 5
weeks after MI (Figure III in the online-only Data Supple-
ment). Finally, we tested CNKASEAMACEL, an inactive
variant of UM206, in the infarct model to exclude nonspecific
effects of peptide administration. The results in this group did
not significantly differ from those of the saline-treated group.
UM206 Treatment Improved the Characteristics of
the Infarct Area
UM206 treatment profoundly reduced infarct expansion and
ventricular dilatation compared with saline treatment. This
was confirmed by histological analysis of the infarct area
(Figure 5A1 and 5A2). The infarct areas were significantly
smaller in UM206-treated than saline-treated mice (Figure
5B) at both 2 and 5 weeks after MI. Moreover, as shown in
Figure 5C, the infarct areas were significantly thicker in the
UM206-treated mice at both time points. Myofibroblast
Figure 3. Wound assay, in which the migration of cardiac fibroblasts immortalized with telomerase (CFIT) into a scratch in the cell layer
was studied under different conditions. Overexpression of Frizzled (Fzd)-1 (A) or -2 (B) alone or in combination with Wnt3a or Wnt5a
significantly attenuated the CFIT migration. This attenuation of the migration could be counteracted by addition of UM206 (100 nmol/L).
The effect of Wnt3a and Wnt5a on CFIT transfected with Fzd-2 is shown in C, as published previously by our group.17 As shown in D,
these effects can be blocked completely by addition of UM206 (10 nmol/L) to the culture medium. All results are the average of 3 inde-
pendent triplicate measurements and are represented as meanSEM (**P0.01, ***P0.001). Statistical test: A and B, 2-way ANOVA;
C and D, 1-way ANOVA, both with Bonferroni correction. Ctrl indicates control.
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numbers were 4-fold higher in the UM206-treated mice at
both time points (Figure 5D). The higher myofibroblast
numbers in the UM206-treated group could be confirmed by
significantly higher -smooth muscle actin levels in the
5-week-old UM206-treated infarcts, as determined by quan-
titative polymerase chain reaction (Figure 5E1) and Western
blotting (Figure 5E2). Moreover, UM206 treatment (5 weeks)
resulted in an increase amount of blood vessels (Figure 5F)
and reduced total collagen levels (Figure 5G) in the infarct
area compared with saline treatment. Collagen I1 expression
was significantly upregulated, whereas collagen III expres-
sion was significantly downregulated (Figure IV in the
online-only Data Supplement). To further investigate whether
UM206 has a direct effect on blood vessel formation, we
analyzed its effects on human umbilical vein endothelial cell
(HUVEC) differentiation and migration. UM206 by itself had
no effect on either of these 2 processes and also did not affect
the increased HUVEC proliferation induced by Wnt3a. The
combination of Wnt3a and UM206 attenuated the HUVEC
migration, whereas individually the compounds did not have
a significant effect (Figure V in the online-only Data Supple-
ment). These results suggest that UM206 does not have a
direct stimulating effect on angiogenesis in the infarct area.
In our experiments, we did not observe any effects of UM206
on other organs known to contain Fzd-2, including kidney and
small intestine. Quantitative polymerase chain reaction of sev-
eral Wnt target genes revealed no difference in the expression
levels of these genes in animals treated with UM206 for 5 weeks
(Table III in the online-only Data Supplement). The difference in
myofibroblast numbers could not be attributed to a difference in
apoptosis, as determined by active caspase-3 immunohistochem-
istry (UM206 treated, 1.600.12%; saline treated, 1.83
0.75%). UM206 treatment caused a significant increase in Fzd-1
and -2 expression, whereas the expression of Wnt3a and Wnt5a
was reduced in this group (Figures VI and VII in the online-only
Data Supplement).
Blocking of Rhodamine-Labeled UM206 Binding
by UM207 and Wnt3a
To demonstrate that the binding site of UM206 on Fzd is
shared with UM207 and Wnt3a, we synthesized rhodamine-
labeled UM206. Attachment of rhodamine to Lys3 of UM206
did not affect its IC50 value for blocking Wnt3a-induced
luciferase expression in HEK293 superTOPflash cells (not
shown). As shown in Figure VIII in the online-only Data
Supplement, incubation of frozen sections of mouse kidney
and gut with UM206 rhodamine (10 nmol/L) for 15 minutes,
followed by rinsing in ice-cold phosphate-buffered saline,
revealed staining of tubular epithelium and villi as assessed
Figure 4. UM206 improves survival and
reduces the deterioration of cardiac func-
tion after myocardial infarction (MI) in
mice. A, Kaplan-Meier plot of the effect of
UM206 treatment on the survival rate of
mice in which MI was induced at t0.
UM206 treatment completely prevented
the mortality after infarction, whereas in
saline-treated mice the mortality was
35% after 5 weeks (n18 animals per
group). B, Increased lung weight in the
saline-treated group is indicative of heart
failure in the mice that survived for 5
weeks after MI. UM206 treatment signifi-
cantly reduced this increase in lung
weight. C1 and C2, Echocardiographic
measurements of ejection fraction and
end-diastolic volume show improved car-
diac function in the UM206-treated group.
D1 and D2, Hemodynamic measurements
indicate that cardiac function was signifi-
cantly better preserved after UM206 treat-
ment compared with saline treatment. All
data are represented as meanSEM.
Sample sizes in B through D were 18 in
the UM206-treated and 12 in the saline
group (*P0.05, **P0.01, ***P0.001).
See also Figure II in the online-only Data
Supplement. Survival curves were calcu-
lated by the Kaplan-Meier method. Statis-
tical analysis of the survival curves was
performed with the log-rank test. Data in
B through D2 were analyzed with 1-way
ANOVA with Bonferroni correction.
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Figure 5. Characteristics of the infarct area in mice treated with UM206. A1 and A2, Transverse sections of a UM206-treated and saline-
treated heart, stained with hematoxylin-eosin. The infarcts were less expanded and thicker after UM206 treatment. Enlarged images repre-
sent myofibroblasts stained for -smooth muscle actin (-SMA). B, Infarct areas were smaller in the UM206-treated group after both 2 and 5
weeks. C, Wall thickness of the infarct area, however, was increased in UM206-treated mice. D, The infarct area of UM206-treated mice con-
tained a 4-fold higher number of myofibroblasts. E1 and E2, To support the histological data, -smooth muscle actin content was deter-
mined both at RNA (quantitative polymerase chain reaction [qPCR]) and protein (Western blot [WB]) levels. These results confirm the immu-
nohistochemical data, in which myofibroblast numbers were found to be increased after UM206 treatment. F, UM206 treatment increases the
neovascularization of the infarct area, as reflected by an increased blood vessel/tissue area ratio. G, Collagen content was decreased after
UM206 treatment. All results are the mean of 18 animals per group and are represented as meanSEM (*P0.05, **P0.01, ***P0.001).
See also Table II in the online-only Data Supplement. Statistical analysis: Student t test.
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by 2-photon microscopy. Specificity of the binding site was
tested by prior incubation of the tissue sections with UM207
(100 nmol/L) or recombinant Wnt3a (10 nmol/L). Both
compounds abolished the binding of UM206 rhodamine to its
receptors but left the green autofluorescence of blood vessels
unaffected. These data strongly suggest that UM206, UM207,
and Wnt3a utilize a shared binding site on Fzd.
Discussion
In this article, we describe the identification of peptidergic
Frizzled antagonists based on regions of high homology
between Wnt3a and Wnt5a. Using predefined criteria, we
identified UM206 through UM208, which all can block the
activation of Fzd-1 and -2 by Wnt3a and Wnt5a. All 3
peptides feature 2 Cys residues, separated by 4 to 10 amino
acids. Gly, Asp, and Thr residues are present in all 3 peptides
and were shown to be important in the blocking effect of
UM206. Because UM206 showed the highest affinity, we
used this peptide in the remainder of the experiments. Either
of the 2 Cys residues of UM206 could be replaced by Ala
with little consequence for the binding, but replacing or
blocking both Cys residues caused complete loss of activity.
This may suggest a covalent interaction between a Cys
residue of the compound and the Cys-rich domain of the
receptor, which will be the subject of further study.
In our experiments, we observed that UM206 could block
the effects of both Wnt3a and Wnt5a with high potency in
different cell lines. Wnt3a can activate the canonical (-
catenin–mediated) pathway, whereas Wnt5a is generally
believed to activate noncanonical Wnt signaling.3 Moreover,
we have shown previously that the effect of Wnt3a and
Wnt5a on CFIT migration is through noncanonical signal-
ing,17 whereas the readout of the HEK superTOPflash cell
line is directly linked to canonical Wnt signaling. Therefore,
we conclude that UM206 can effectively antagonize both
canonical and noncanonical Wnt signaling.
UM206 administration had a beneficial effect on infarct
healing. It increased myofibroblast and blood vessel numbers
in the infarct area, prevented infarct expansion, improved
cardiac function, and completely prevented heart failure–
related mortality. Thus far, the role of Wnt signaling in infarct
healing has only been studied by genetic interventions.
Barandon et al21 were the first to show a beneficial effect of
overexpression of FrzA, a bovine homologue of soluble
Frizzled-related protein-1, on infarct healing. They observed
a decreased infarct size with elevated numbers of myofibro-
blasts and blood vessels. Similar results were reported by
Kobayashi et al22 in mice lacking soluble Frizzled-related
protein-2. However, in the latter study it was concluded that
this was the result of a direct effect of soluble Frizzled-related
protein-2 on procollagen-C-proteinase rather than blocking of
Wnt signaling. This underscores that the role of soluble
Frizzled-related proteins in infarct healing is complex and
may not solely be the result of Wnt inhibition. We did not
observe any adverse effects of long-term UM206 administra-
tion, indicating that this therapeutic intervention is safe and
does not interfere with normal physiological processes.
In most of our in vivo experiments, we started the admin-
istration of UM206 directly after induction of the infarct. This
raised the question of whether starting directly after infarction
is critical for a beneficial effect. To investigate this, we
started UM206 therapy at 2 weeks after MI in a separate
group of mice and euthanized them at 5 weeks. The effect of
this “late” treatment on hemodynamic parameters was similar
to a full 5-week treatment (Figure III in the online-only Data
Supplement). This observation is not only of importance for
a potential therapeutic application of UM206 but also may
suggest that the effect of UM206 is not primarily directed to
the early phases of infarct healing (cardiomyocyte death and
inflammatory response23).
The role of myofibroblasts in wound healing and tissue
repair is well established. These cells are responsible for the
contraction of skin wounds, thereby limiting the size of the
scar that is formed at the site of injury.24 More recently, a
similar role has been described for myofibroblasts in the
infarct area,23,25–28 thereby preventing infarct expansion.19,29
Moreover, myofibroblasts remain present in well-healed hu-
man infarcts for decades but are scarce in dilated infarcts
obtained from heart failure patients.30 Previously, we have
shown that myofibroblasts express Fzd-1 and -2 during their
migration into the infarct area.20 Overexpression of compo-
nents of the Wnt/Fzd pathway affects the differentiation and
migration of CFIT.17 Therefore, our data suggest that Fzd-1
and -2, expressed during infarct healing,20 may play a
functional role in the wound healing process after MI and
may serve as a therapeutic target for intervention in this
process. Moreover, the results of the present study may
highlight the importance of increasing myofibroblast num-
bers to preserve cardiac function in the remodeling heart,23,31
although we cannot exclude that UM206 targets other cell
types in the healing infarct as well. UM206 may serve as a
lead for the development of a novel drug class that addresses
the process of infarct healing. This is of particular importance
because the drugs that are currently available for the treat-
ment of MI cannot prevent infarct expansion in all patients.32
UM206 therapy increased the blood vessel density in the
infarct area. A role of Wnt signaling in blood vessel devel-
opment has been reported previously by our group33 and
others,34 and increased blood vessel formation was also
observed in FrzA-overexpressing mice subjected to infarc-
tion.21 To study a potential direct effect of UM206 on blood
vessel formation, experiments with HUVEC were performed.
UM206 by itself had no effect on HUVEC proliferation and
migration. Moreover, UM206 could not block the Wnt3a-
induced increase in HUVEC proliferation. On the other hand,
the combination of UM206 and Wnt3a attenuated the HUVEC
migration. Taken together, these data suggest that UM206 does
not have a direct proangiogenic effect in the healing infarct.
Interestingly, angiogenesis has been reported to be Fzd4 and
Fzd5 dependent,34 and UM206 was shown to have no effect on
this Frizzled family member in the present study. A possible
explanation for our observations is that the increase in vessel
density in the infarct area may be secondary to the demand for
oxygen and nutrients of the myofibroblasts in the infarct area,
thereby improving the survival of these cells.
Previously, we studied the effects of activation of the
Wnt/Frizzled pathway on CFIT in more detail.17 In this study,
we observed that migration of CFIT was reduced when
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Wnt3a or Wnt5a was added to the culture medium, an effect
that could be blocked completely with UM206. When we
extrapolate this to our in vivo data, this mechanism may
contribute to the increased myofibroblast numbers in the
infarct area on UM206 treatment. Moreover, we observed a
profound change in the relative expression levels of collagen
Ia1 and collagen III in the UM206-treated animals (Figure IV
in the online-only Data Supplement). Collagen I is known to
resist distension better than collagen III,35 which is likely to
contribute to the better preservation of the left ventricular
dimensions in the UM206-treated group.
Rhodamine-labeled UM206 was used to investigate the
binding site of UM206 and UM207 on Fzd-1 and -2 in kidney
and small intestine. The binding of rhodamine-labeled
UM206 could be prevented by preincubation with either
Wnt3a or UM207. These results strongly suggest that
UM206, UM207, and Wnt3a occupy the same binding site on
the Fzd-1 and -2 proteins. Therefore, the effects of UM206
and UM207 most likely can be attributed to competition with
Wnts for binding to the Fzd-1 or -2 protein.
In the present study, we observed a beneficial effect on
cardiac remodeling and function of UM206, and we tried to
identify its mechanism of action by performing in vitro
experiments. However, these experiments face several limi-
tations. Our in vitro data suggest that myofibroblasts may be
the most likely target of UM206, but these data were
generated with the use of the immortalized cardiac fibroblast
cell line CFIT, overexpressing either Fzd-1 or Fzd-2, as a
model system. We could not use primary cultures of cardiac
fibroblasts for this purpose because they differentiate spon-
taneously into myofibroblasts in culture and are difficult to
transfect. Therefore, these experiments do not provide formal
proof that (myo)fibroblasts in the infarct area are the only
target of UM206 in vivo. We also observed an increase in
blood vessel density in the infarct areas of UM206-treated
mice. In the in vitro experiments with HUVEC, UM206 had
no direct effect on endothelial cell proliferation and differen-
tiation, but these data were generated with the use of
untransfected cells and therefore may not be directly compa-
rable to the CFIT data. Finally, we cannot rule out an effect
of UM206 on the inflammatory response after MI. Therefore,
additional experiments will be needed to draw firm conclu-
sions regarding the target(s) and the mechanism of action of
UM206 in the healing infarct.
In conclusion, the present study shows that fragments of
Wnt proteins can serve as high-affinity Frizzled antagonists.
Moreover, blocking of Frizzled can be a successful and safe
approach to prevent infarct expansion. Specifically targeting
the wound-healing process in the infarcted heart may serve as
a novel and promising approach to prevent heart failure
development in MI patients.
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CLINICAL PERSPECTIVE
Myocardial infarction is one of the major causes of heart failure. The scar in the infarct area shows a progressive thinning
in these patients, causing excessive dilatation of the entire left ventricle, which leads to pump failure. This dilatation can
be attributed to the repetitive mechanical strain that the cardiac cycle places on the scar, causing wear of the extracellular
matrix in the scar tissue. Previous work from our laboratory and others has highlighted the importance of myofibroblasts
in the maintenance of this scar: The smooth muscle-like contractile properties of these cells provide a sustained contractile
force that is subsequently anchored by the deposition of extracellular matrix. In this article, we propose the targeting of
myofibroblasts as a novel therapeutic approach to prevent infarct-related heart failure. We have shown previously that
myofibroblasts in the infarct area express Frizzled receptors. The receptors use Wnt proteins as their endogenous ligands.
Here we describe a fragment of Wnt5a, named UM206, that blocks the interaction between Wnt and Frizzled with high
affinity. When administered to infarcted mice, UM206 completely prevented heart failure development. Moreover, infarct
thinning and left ventricular dilatation were significantly reduced by UM206, which may be explained by a 4-fold increase
in myofibroblast numbers in the infarct area. This study shows that Frizzled blockers may be a novel drug class that can
prevent heart failure development after myocardial infarction.
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Extended Methods 
 
Western blotting 
For Western blot, cells were homogenized in ice-cold Laemmli buffer and protein content 
was measured using the BCA protein assay (Pierce Biotechnology Inc., Rockford IL, 
USA); proteins were denatured by boiling, separated on a 10% SDS-page gel, and 
transferred onto a Hybond C nitrocellulose membrane (Amersham Biosciences, Little 
Chalfont, United Kingdom). After blocking, membranes were incubated overnight at 4°C 
with primary antibodies against β-catenin, α-SMA (both 1:2000, BD Biosciences, 
Franklin Lakes NJ, USA) or β-actin (1:2000 Sigma-Aldrich). Anti-mouse 
immunoglobulin G 1/5000 (Vector Labs Inc.) was used as the secondary antibody, and 
the membranes were developed using the Supersignal West Pico chemiluminescence kit 
(Pierce). Images of the blots were analyzed with image analysis software (Qwin Leica, 
Cambridge, United Kingdom). 
 
Echocardiography 
All mice were subjected to repeated echocardiographic assessment of wall thickness, LV 
cavity dimensions and ventricular function. Echocardiograms were recorded with Philips 
Sonos 5500 ultrasound system (Philips, Eindhoven, the Netherlands) using a 20-MHz 
linear probe under light isoflurane anaesthesia (2%).  
 
Hemodynamic measurements 
The animals were anaesthetized with urethane (2.5 mg/g body weight, i.p., Sigma-
Aldrich). Mice were intubated and connected to a rodent ventilator (Hugo Sachs, March-
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Hugstetten, Germany). Body temperature was maintained at 37°C. The mice were then 
allowed to stabilize prior to hemodynamic measurements. A high-fidelity catheter tip 
micromanometer (Mikro-tip1.4F, SPR-671; Millar Instruments, Houston TX, USA) was 
inserted through the right carotid artery into the left ventricular cavity. Ventricular 
pressure was measured. Maximal positive and negative pressure development (+dP/dt 
and –dP/dt) and heart rate were determined on a beat-to-beat basis. The heart was then 
stimulated by an i.v. ramp-infusion of dobutamine (Sigma-Aldrich, dose range 20-100 
µg) using a micro-injection pump (Model 200 Series, KdScientific, Boston, MA, USA).  
 
Peptide Fragment Synthesis 
All peptide fragments were synthesized by manual solid-phase peptide synthesis on a 0.3-
0.4 mmol scale using the in situ neutralization/activation procedure for Boc-/Bzl- peptide 
synthesis as previously described 42, but using HCTU instead of HBTU as a coupling 
reagent. MBHA-polystyrene resin (1 meq/g) was used as the solid support. The peptides 
were deprotected and cleaved from the resin by treatment with anhydrous HF for 1 h at 0° 
C, using 4 vol-% p-cresol as a scavenger.  
Following cleavage, the peptides were precipitated with ice-cold diethylether, dissolved 
in aqueous buffer containing 6 M Gn.HCl, 0.1 M sodium acetate buffer (pH 4) and 
purified by semi-preparative reversed-phase HPLC. Fractions containing the desired 
product were identified by ESI-MS, pooled and lyophilized. 
 
HPLC 
 by guest on March 28, 2012http://circ.ahajournals.org/Downloaded from 
To determine the plasma concentration of UM206, reached by subcutaneous infusion 
with the minipumps, blood samples were collected from the animals after 14-35 days 
treatment. Blood was centrifuged and the plasma was treated with 1% TFA. Analytical 
HPLC was performed using a Vydac C18 RP-HPLC column (4.6 mm × 150 mm, 1 
mL/min flow rate) connected to a Varian Prostar system consisting of two Varian Prostar 
215 delivery modules and a Varian Prostar 320 UV/vis detector (214 nm). A linear 
gradient of 0-67% buffer B in buffer A over 30 minutes was used, where buffer A = 0.1 
v-% TFA in H2O and buffer B = 0.1 v-% TFA, 10 v-% H2O in CH3CN. 
Semi-preparative HPLC was performed using Vydac C18 RP-HPLC columns (10 
mm × 250 mm, 5 mL/min flow rate or 22 mm x 250 mm, 10 mL/min flow rate) 
connected to a Waters Deltaprep System consisting of a Waters Prep LC Controller and a 
Waters 2487 Dual wavelength Absorbance Detector (214 nm). Peptides were eluted using 
a shallow gradient of B in A, based on an exploratory analytical HPLC run. 
 
HUVEC isolation and culture  
Primary human umbilical vein endothelial cells (HUVECs) were isolated by infusion of 
trypsin into the umbilical vein which was first washed 3 times by perfusion of PBS. 
Following trypsin incubation for 20 minutes at 37°C, the cells were collected in HUVEC 
culture medium (RPMI (Invitrogen) containing 10% fetal calf serum (Invitrogen) and 
10% human serum, supplemented with L-glutamin (Invitrogen) and 
penicillin/streptomycin (Invitrogen)). Next, the trypsin/collection medium mixture was 
removed by centrifugation for 5 minutes at 400 g. The cells were resuspended in fresh 
HUVEC culture medium and allowed to adhere for 1 hour at 37°C/5% CO2 in culture 
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flasks coated with 0.2% gelatine/PBS. Finally, unattached cells and erythrocytes were 
removed by stringent washing with PBS. Cells were maintained in HUVEC medium at 
37°C/5% CO2 and passaged 1:3 upon confluence. 
 
HUVEC proliferation 
Proliferation analysis of HUVEC was performed using the CellTiter-Glo® Luminescent 
Cell Viability Assay (Promega). In brief, cells were plated in gelatin coated 96-wells 
plates at a density of 5000 cells/well. Next, standard culture medium was replaced with 
starvation medium (1% HS/1%FCS) and cells were treated for 3 days with the different 
compounds at the indicated concentrations. Following the treatment period, CellTiter-
Glo® analysis was performed according to the suppliers protocol and luminescence was 
recorded on a Tecan Infinite F200 multimode microplate reader (Tecan Group Ltd.). All 
treatment conditions were performed in triplicate on three different primary HUVEC 
isolations.  
 
HUVEC migration 
Migration of HUVEC was analyzed using the scratch wound assay. In brief, cells were 
plated in gelatin coated 96-wells plates at a density of 5000 cells/well. Following three 
days of growth in standard culture medium the endothelial cell monolayer was scratched 
using the HTSScratcher (Peira) and medium was replaced with starvation medium (1% 
HS/1%FCS) containing the different compounds at the indicated concentrations. Images 
of each scratch were automatically acquired at t = 0 and t = 6 hours with a 1.4 Mb GiGE 
color camera (Hitachi) on a DMI3000B microscope equipped with an automated xyz-
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stage (Leica) using Universal Grab software (version6.3, DCIlabs). Scratch area was 
determined using Scratch Assay software (version6.2, DCIlabs). All treatment conditions 
were performed in triplicate on three different primary HUVEC isolations.  
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Figure legends 
Fig. S1: UM206 completely blocks the Wnt3a-induced luciferase activity in CHO (A) 
and COS-7 (B) cells, transiently transfected with a TopFlash construct. rFzd-1 and -2 
were transfected into these cells as indicated. 
 
Fig. S2: Plasma concentration-time curve of a single intravenous bolus injection of 15 
microgram of UM206 in the tail vein of mice (N = 24). The plasma half-life was 84 ± 2 
min 
 
Fig. S3: Effect of late onset of UM206 treatment on the hemodynamic parameters. 
UM206 treatment (6 µg/kg.day, subcutaneous administration by osmotic minipump, n=8 
per group) was started at 2 weeks after MI and continued until the end of the 5 week 
experiment. Please note that the effect of the late onset UM206 treatment was comparable 
to the full 5-week treatment depicted in Fig. 4. 
 
Fig. S4: Administration of UM206 for 5 weeks results in a significant increase in the 
expression of Collagen Iα1 (Col Ia1) and a significant decrease in the expression of 
Collagen III (Col III). *** P<0.001 
 
Fig. S5: Effect of UM206 on Human Umbilical Vein endothelial cell (HUVEC) 
proliferation and migration. HUVEC proliferation was stimulated by Wnt3a (1.10-8 M), 
and this effect was not blocked by UM206, whereas the anti-angiogenic peptide Anginex 
(1.10-5 M) caused a clear attenuation of the proliferation. Stimulation with 20% human 
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serum (HS) was used as positive control. UM206  by itself did not affect HUVEC 
migration, which was stimulated by 20% HS. The combination of UM206 and Wnt3a 
even caused an attenuation of HUVEC migration. From these data we conclude that 
UM206 has no direct stimulatory effect on angiogenesis.  
 
Fig S6: Expression levels of different Fzd subtypes in the infarct area, 5 weeks after 
induction of MI. Please note that MI induces an increase in the expression of Fzd-1 and -
2 and that this effect is augmented by UM206 administration 
 
Fig S7: Effect of UM206 treatment on the expression of Wnt proteins in the infarct area, 
5 weeks after MI. Administration of UM206 almost completely returns the expression of 
Wnt3a and 5a, upregulated by MI, to the levels observed in sham animals. 
 
Fig. S8:  Binding of UM206-Rhodamine to Frizzled-1 and -2 can be blocked by UM207 
and Wnt3a. A. Fluorescent signal of UM206-Rhodamine binding to small intestine and 
kidney is shown in red; green represents autofluorescence of blood vessels in the tissue.  
B. Small intestine and kidney imaging after pre-incubation with UM207 (100 nM) c. 
Small intestine and kidney after pre-incubation with the natural ligand Wnt3a (10 nM). 
Bar represents 100 µm. 
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Table S1 
 
Genes Primers forward Primers reverse 
α-actin CAGCTGAGAGGGAAATCGTG 
 
CGTTGCCAATAGTGATGACC 
 
Ascl-2 AAGCACACCTTGACTGGTACG  
 
AAGTGGACGTTTGCACCTTCA  
 
α-SMA AACTGGTATTGTGCTGGACTCTGG 
 
CACGGACGATCTCACGCTCAG 
 
Axin 2 TGACTCTCCTTCCAGATCCCA  
 
TGCCCACATAGGCTGACA  
 
CD 44 TCTGCCATCTAGCACTAAGAGC GTCTGGGTATTGAAAGGTGTTAGC  
 
Collagen I TCGATTCACCTACAGCACGC 
 
GACTGTCTTGCCCCAAGTTCC 
 
Collagen III TCCTGAACATGTCCTTTGATGTA 
 
TTCAGAGACTTCTTTACATTGCCATT 
 
Cyclophilin TTCCTCCTTTCACAGAATTATTCCA 
 
CCGCCAGTGCCATTATGG 
 
Dickkopf 1 TAGTCCCACCCGCGGAGGGGA 
 
CTTCTGGAATACCCATCCAA 
Dickkopf 2 GGATCTTCAGCCTGCATGGT 
 
GGGCAACACATCCCATCTCT 
 
Dickkopf 3 TCAGGAGGAAGCTACGCTCAA 
 
GGTCACCTCAGAGGACGTTCTAG 
 
Dvl 2 ACTGGTGCGGTCTAGGTTTTGA 
 
GGAAGACGTGCCCAAGGA 
 
Fibronectin TGTCACCCACCACCTTGA 
 
CTGATTGTTCTTCAGTGCGA 
 
Fibronectin ED-A ACCATTGAAGGTTTGCAACC 
 
GGAGGTGCTGTCTGGAGAAA 
 
Fibronectin ED-B AGAATAACCACCACCCCCA 
 
TGTTAGGACCACGGCGTT 
 
Inos CATCCAGAGTGAGCTGGTAGG 
 
GCTGGTAGGGGCAAAAATAGAGGAAC
ATCT 
Itm 2A AGGAGAGCCATACTTTCTGCC GCCGGATCGCTATCAGAGAGA 
LEF CACACATCCCGTCAGATGTC 
 
TGATGGGATAAACAGGCTGA 
 
MMP 7 CTGCCACTGTCCCAGGAAG 
 
GGGAGAGTTTTCCAGTCATCG 
Twist CTCGGACAAGCTGAGCAAG 
 
ACGGAGAAGGCGTAGCTGAG 
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Fig. S1
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Table S2
 Wnt-derived peptides that were ineffective in antagonizing  Fzd-1 and -2
 sequence 
Peptide 1 Ac-CKCHGVSGSCTVKTCW -NH2 
Peptide 2 Ac-MNRHNNEAGR-NH2 
Peptide 3 Ac-IEECQHQFRDRRWNC -NH2 
Peptide 4 Ac-GDWEWGECSDNI-NH2 
Peptide 5 Ac-DLVYFELSPDFCA-NH2 
Peptide 6 Ac-GSKGTQGRACN-NH2 
Peptide 7 Ac-CNKSGMDGCEL-NH2 
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Fig. S3 
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Fig. S4 
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Fig. S5 
 
 
 
 by guest on March 28, 2012http://circ.ahajournals.org/Downloaded from 
 Table S3
small intestine  
Gene Saline 
Rel. exp. 
 
SEM 
UM206 
Rel. exp. 
 
SEM 
 
significance 
Ascl 2 1.44 0.01 1.42 0.01 - 
Dvl 2 1.13 0.03 1.13 0.04 - 
Inos 1.19 0.01 1.18 0.02 - 
Col I 1.35 0.01 1.32 0.01 - 
CD 44 1.27 0.02 1.22 0.02 - 
Axin 2 1.08 0.04 1.05 0.04 - 
Itm 2A 0.99 0.05 0.97 0.05 - 
Mmp 2 1.34 0.01 1.32 0.01 - 
kidney 
Gene Saline 
Rel. exp. 
 
SEM 
UM206 
Rel. exp. 
 
SEM 
 
significance 
Twist 1.45 0.03 1.49 0.03 - 
α-actin 1.04 0.01 1.06 0.02 - 
LEF 1.66 0.02 1.70 0.09 - 
FN 1.62 0.01 1.66 0.01 - 
Col I 1.38 0.03 1.39 0.01 - 
α-SMA 1.18 0.03 1.21 0.04 - 
DDK 1 1.83 0.01 1.87 0.01 - 
DDK 2 1.40 0.01 1.44 0.01 - 
DDK 3 0.85 0.01 0.87 0.01 - 
 
Effects of 5 week UM206 treatment on the expression levels of genes in small intestine 
and kidney, for which the expression is known to be regulated by Wnt signaling. The 
expression levels were determined by qPCR. None of the investigated genes showed a 
significant change in expression compared to saline treatment. 
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Fig. S6 
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Fig. S7 
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